| 翻訳と辞書 |
Iclaprim
Iclaprim (INN), codenamed AR-100 and RO-48-2622, is a diaminopyrimidine dihydrofolate reductase (DHFR)-inhibiting extended-spectrum antibiotic active against gram positive organisms being developed for the treatment of complicated skin and soft tissue infections caused by antibiotic-resistant bacteria. It is structurally related to trimethoprim. In Phase III clinical trials, intravenously-administered iclaprim was found to be as effective as and better tolerated than linezolid in people with skin and soft tissue infections, many caused by methicillin-resistant ''Staphylococcus aureus'' (MRSA). ''In vitro'', iclaprim is highly active against MRSA, vancomycin-resistant ''Staphylococcus aureus'' (VRSA), strains of ''Streptococcus pneumoniae'' resistant to several common antibiotics, and some Gram-negative bacteria.
A new drug application for iclaprim was filed with the U.S. Food and Drug Administration in March 2008,〔 and a marketing authorisation application (MAA) was accepted by the European Medicines Agency on August 21, 2008. Phase II clinical trials are being conducted to assess whether iclaprim can be taken by mouth as well as intravenously and whether it is effective for the treatment of hospital-acquired pneumonia.〔
Iclaprim was granted fast track status by the FDA, but approval of the drug was eventually declined in 2009〔(Arpida receives FDA complete response letter for Iclaprim )〕 and no further development has taken place since then.
In Jan 2015, Motif BioSciences gained rights to iclaprim and planned to continue its development.
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Iclaprim」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|